Aquaporins have multiple distinct roles in mammalian physiology. Phenotype analysis of aquaporin-knockout mice has confirmed the predicted role of aquaporins in osmotically driven transepithelial fluid transport, as occurs in the urinary concentrating mechanism and glandular fluid secretion. Aquaporins also facilitate water movement into and out of the brain in various pathologies such as stroke, tumour, infection and hydrocephalus. A major, unexpected cellular role of aquaporins was revealed by analysis of knockout mice: aquaporins facilitate cell migration, as occurs in angiogenesis, tumour metastasis, wound healing, and glial scar formation. Another unexpected role of aquaporins is in neural function -in sensory signalling and seizure activity. The water-transporting function of aquaporins is likely responsible for these roles. A subset of aquaporins that transport both water and glycerol, the 'aquaglyceroporins', regulate glycerol content in epidermal, fat and other tissues. Mice lacking various aquaglyceroporins have several interesting phenotypes, including dry skin, resistance to skin carcinogenesis, impaired cell proliferation, and altered fat metabolism. The various roles of aquaporins might be exploited clinically by development of drugs to alter aquaporin expression or function, which could serve as diuretics, and in the treatment of brain swelling, glaucoma, epilepsy, obesity and cancer.
High-resolution structures have been obtained for several AQPs, and show the assembly of AQP monomers in tetramers, with individual monomers containing six tilted a-helical domains forming a barrel-like structure in which the first three and last three helices exhibit inverted symmetry (Refs 1, 2). Molecular dynamics simulations suggest tortuous, single-file passage of water through a narrow ,0.3 nm pore, in which steric and electrostatic factors prevent transport of protons and other small molecules (Ref. 3) . AQPs 1, 2, 4, 5 and 8 are primarily water selective, whereas AQPs 3, 7 and 9 (called 'aquaglyceroporins') also transport glycerol and possibly other small solutes. Water transport by some AQPs is inhibited by nonspecific, cysteine-sulphydral-reactive compounds such as mercuric chloride (HgCl 2 ). There is considerable interest, although little reported progress, in the identification of nontoxic AQP-selective inhibitors, which could serve as valuable research tools and clinical therapies.
Tissue distribution and regulation studies have provided indirect evidence for the involvement of AQPs in a variety of physiological processes. In the case of AQP2, nephrogenic diabetes insipidus in subjects with AQP2 mutations indicated the requirement of AQP2 for the formation of a concentrated urine (Ref. 4) . Much of the knowledge of AQP functions in mammalian physiology has come from phenotype analysis of mice lacking the various mammalian AQPs. One paradigm that has emerged is that tissue-specific AQP expression does not mandate AQP involvement in a physiologically important process, as was found for several AQPs in lung (Ref. 5 ) and intestine (Ref. 6 ), AQP4 in skeletal muscle (Ref. 7) , AQP5 in sweat gland (Ref. 8) , and AQP8 in multiple tissues (Ref. 9) . Functional analysis of cells and tissues from knockout mice has also tested proposed roles of AQPs in gas transport and intracellular organellar function, as well as in AQP protein -protein interactions. Although there is evidence that some AQPs may allow transport of CO 2 and NH 3 (Refs 10, 11), physiological studies in mice and transport measurement in isolated tissues have provided evidence against a physiologically significant role of AQPs in gas transport (Refs 12, 13, 14) . Negative data were also found for the proposed involvement of AQPs in mitochondrial function (Ref. 15 ) and in a key AQP protein -protein interaction in the central nervous system -a proposed interaction between AQP4 and the inwardly rectifying K þ channel Kir4.1 responsible for K þ ion uptake by glial cells during neuroexcitation (Refs 16, 17) .
Balancing the many negative phenotype studies, data from knockout mice implicate important roles of AQPs in kidney, brain, eye, skin, fat and exocrine glands, suggesting their involvement in major organ functions and disease processes, including urinary concentrating, brain swelling, epilepsy, glaucoma, cancer and obesity. This reviews focuses on these AQP roles and their significance in normal organ physiology and disease. Figure 1 provides a schematic summary of the various AQP roles in mammalian physiology, and is referred to in the various sections below.
Epithelial fluid transport Active fluid secretion and absorption
AQPs are expressed in many epithelia, such as kidney tubules, glands, choroid plexus, ciliary body and alveoli, where they increase transepithelial osmotic water permeability. One consequence of increased transepithelial water permeability is active (also referred to as 'facilitated' or 'near-isosmolar') fluid secretion and absorption. Active fluid transport involves the creation of an osmotic gradient (generally quite small) across an epithelium by active ion/solute transport, which drives water transport through highly water-permeable epithelial cell membranes (Fig. 1a) . Reduced epithelial cell osmotic water permeability can consequently impair active fluid transport and osmotic water equilibration, resulting in the secretion (or absorption) of a reduced volume of inappropriately hypertonic fluid. This prediction has been confirmed in AQP5-knockout mice in salivary gland (Refs 18, 19) and airway submucosal gland (Ref. 20) . Defective fluid secretion has also been found in AQP1-knockout mice in choroid plexus (Ref. 21) , which produces cerebrospinal fluid, and in ciliary epithelium (Ref. 22) , which produces ocular aqueous fluid. In each of these systems the rate of transepithelial fluid secretion, normalised to epithelial surface area, is very high, such that the reduced but nonzero water permeability in AQP deficiency impacts on transepithelial osmotic equilibration. Of note, because of the substantial intrinsic water permeability of lipid bilayers, AQP deficiency is generally not associated with more than a five-to tenfold reduction in transepithelial osmotic water permeability. Very rapid, active transepithelial fluid absorption occurs in kidney proximal tubule, where the majority of fluid filtered by the glomerulus is reabsorbed. Proximal-tubule fluid absorption is impaired in mice lacking the proximal-tubule water channel 
Osmotic equilibration across kidney tubules and the urinary concentrating mechanism
Another anticipated role of AQPs is in water transport across kidney tubules and microvessels (vasa recta), which is required for the formation of a concentrated urine. The major AQPs expressed in the kidney are AQPs 1, 2, 3, 4 and 7 (Fig. 2a) . Deletion of the genes for AQP1 and/or AQP3 in mice results in marked polyuria, as seen in 24 h urine collections (Fig. 2b) (Refs 31, 32) . Measurement of urine osmolalities in mice before and after 36 h water deprivation (Fig. 2c) shows that urinary osmolality in AQP1-null mice is low and does not increase with water deprivation, resulting in severe dehydration. AQP3-null mice are able to generate a partially concentrated urine in response to water deprivation, whereas AQP4-null mice manifest only a mild defect in maximum urinary concentrating ability (Ref. 33) .
AQP1 deletion produces polyuria and unresponsiveness to water deprivation by two distinct mechanisms: impaired near-isosmolar water reabsorption in the proximal tubule, as described above, and reduced medullary hypertonicity resulting from impaired countercurrent multiplication and exchange (a consequence of low water permeability in the thin descending limb of Henle and outer medullary descending vasa recta). Transepithelial osmotic water permeability in the isolated microperfused S2 segment of proximal tubule was reduced by about fivefold in AQP1-knockout mice (Ref. 23) , indicating that most water transport in the proximal tubule is transcellular and AQP1 dependent. AQP1 also provides the major route for transepithelial water permeability in the thin descending limb of Henle and outer medullary descending vasa recta (Refs 34, 35) . These results support the conclusions that AQP1 is the principal water channel in these segments, and that AQP1 plays a key role in the antidiuretic kidney in the generation of the hypertonicity of the medullary interstitium by countercurrent multiplication and exchange. The aquaglyceroporin AQP7 is expressed in a small distal segment (S3 segment) of the proximal tubule; however, its deletion in mice is not associated with significant impairment in urinary concentrating ability, but rather with an impairment of glycerol clearance, whose significance remains unclear (Ref. 36) .
AQP3 and AQP4 are expressed at the basolateral membrane of collecting duct epithelium, with relatively greater expression of AQP3 in cortical and outer medullary collecting duct, and AQP4 in inner medullary collecting duct. In contrast to AQP1 deficiency, countercurrent multiplication 
Urine osmolality (mosM) 
Brain swelling
Another major AQP role related to its water transport function is in brain water balance. AQP4 is expressed in glial cells (astrocytes) throughout the brain and spinal cord, particularly at sites of fluid transport at blood-brain and brain-cerebrospinal-fluid (CSF) interfaces. AQP4 expression is polarised to glial cell foot processes in contact with blood vessels, and in the dense glial cell processes that form the glia limitans lining the CSF-bathed pial and ependymal surfaces in the subarachnoid space and the ventricles. AQP4 provides the major route for water transport across glial cell membranes. Osmotic water permeability in glial cells cultured from AQP4-null mice was sevenfold lower than that from wild-type mice (Ref. 39) . Also, greatly slowed accumulation of brain water was found in AQP4-null mice in response to serum hypoosmolality, as monitored by a noninvasive nearinfrared optical method (Ref. 
Classification of brain oedema
According to the Klatzo classification (Ref. 42 ), brain oedema can be classified as cytotoxic (cell swelling) oedema or vasogenic (leaky vessel) oedema (Fig. 3a) . In cytotoxic oedema, excess water moves from the vasculature into the brain parenchyma through an intact blood -brain barrier. The forces driving water flow to form cytotoxic oedema are osmotic, generated in water intoxication by reduced plasma osmolality, and in ischaemia and other pathologies by impaired Na þ /K þ -ATPase pump function with consequent Na þ and water accumulation in brain cells. When the bloodbrain barrier becomes disrupted (as in brain tumour or abscess), water is driven by hydrostatic forces from the vasculature into the extracellular space of the brain in an AQP4-independent manner to form vasogenic oedema. Excess brain water is eliminated primarily through the glia limiting membrane into the CSF, and to a lesser extent back through the blood -brain barrier into the blood. The blood -brain barrier may become an important route for water elimination in obstructive hydrocephalus when other routes or water exit are impaired.
Cytotoxic brain oedema
Phenotype analysis of AQP4-null mice has provided compelling evidence for AQP4-facilitated brain water accumulation in cytotoxic oedema and for AQP4-facilitated brain water elimination in vasogenic oedema. Water intoxication, produced experimentally in mice by intraperitoneal water injection, is an example of pure cytotoxic oedema in which water is driven osmotically into the brain through an intact blood -brain barrier. AQP4-null mice have remarkably improved survival following water intoxication compared with wild-type mice (Fig. 3b) (Fig. 3d) , probably due to reduced transependymal water clearance (Ref. 48) .
AQP4 is thus a major determinant of fluid movement into and out of the brain. Many brain pathologies, such as impact injury and toxic encephalopathies, produce brain oedema by a combination of cytotoxic and vasogenic mechanisms, each with a different time course and severity, so it is difficult a priori to predict whether and when AQP4 inhibition would be beneficial or detrimental. 
Swelling of ocular tissues

Cornea and lens swelling
In cornea, endothelial cell AQP1 and epithelial cell AQP5 are involved in corneal stromal water balance, and thus maintenance of corneal transparency. Corneal thickness is reduced compared with normal in AQP1-null mice and increased in AQP5-null mice (Ref. 51) . In an experimental model of corneal swelling produced by exposure of the ocular surface to hypo-osmolar fluid, the recovery of corneal transparency and thickness after hypotonic swelling was greatly delayed in AQP1-null mice. AQP1 is also expressed in the epithelial cell layer surrounding the lens, where it plays a role in lens water balance (Ref. 50) . Although AQP1 deletion did not alter baseline lens morphology or transparency, loss of lens transparency was greatly increased in an in vitro model of cataractogenesis produced by incubation of lenses in high-glucose solutions. Cataract formation was also greatly accelerated in AQP1-null mice in an in vivo model of cataractogenesis produced by acetaminophen toxicity. Notwithstanding lack of a clear-cut mechanism for these observations, the results suggest the interesting possibility of reducing corneal and lens oedema by AQP1 upregulation.
Retinal swelling
There is also evidence implicating AQP4 in retinal swelling. AQP4 is expressed in Mü ller cells in retina, where it is involved in light signal transduction (see section 'Neural signal transduction' below). Based on the protection expert reviews http://www.expertreviews.org/ in molecular medicine against cytotoxic brain oedema conferred by AQP4 gene deletion, the possibility was tested that AQP4 deletion protects the retina in a transient ischaemia -reperfusion model produced by 45-60 min elevation in intraocular pressure to 120 mmHg (Ref. 54) . Retinal structure and cell number were remarkably preserved in AQP4-null mice, particularly in the inner nuclear and plexiform layers of retina where Mü ller cells are concentrated. Retinal function and cell survival were also improved in AQP4-null mice, with electroretinographic evidence of significant attenuation of the reduction in b-wave amplitudes. Whether the neuroprotective effects of AQP4 deletion in retina can be exploited in the therapy of human ocular disease remains to be explored.
Cell migration Impaired angiogenesis in AQP1 deficiency
Phenotype analysis of AQP1-null mice led to the discovery of AQP involvement in cell migration. Given the expression of AQP1 in tumour microvessels (Ref. 55) , the involvement of AQP1 in tumour angiogenesis was tested (Ref. 56 ). AQP1 deletion in mice reduced tumour growth following subcutaneous injection of melanoma cells (Fig. 4a) , which was associated with increased tumour necrosis and reduced bloodvessel formation within the tumour bed. In experiments to elucidate the mechanism of defective tumour angiogenesis in AQP1 deficiency, it was found that cultured aortic endothelial cells from AQP1-null mice migrated several-fold slower towards a chemotactic stimulus than AQP1-expressing endothelial cells. Other processes involved in angiogenesis, including endothelial cell proliferation and adhesion, were not impaired in AQP1 deficiency. Transfection of AQP1 or other AQPs into cells that do not express AQPs increased their migration, suggesting the involvement of AQP-facilitated cell membrane water permeability in cell migration. In the migrating cells, AQP1 becomes polarised to the front end of cells (Fig. 4b) , and is associated with increased turnover of cell membrane protrusions (lamellipodia), suggesting that AQPs at the leading edge of migrating cells facilitate their migration. 
Reduced tumour spread, glial scarring and wound healing in AQP deficiency
Mechanisms of AQP-facilitated cell migration
The enhanced cell migration found for multiple structurally different AQPs, independent of their modulation method (transfection, knockout, RNA inhibition), suggests that AQPfacilitated water transport is the responsible mechanism. AQPs might accelerate cell migration by facilitating rapid changes in cell volume that accompany changes in cell shape as cells squeeze through the narrow extracellular space. Water flow across the cell membrane may also allow migrating cells to generate hydrostatic forces to push apart adjacent stationary cells. This mechanism, however, does not account for the polarisation of AQPs to the front end of migrating cells or for AQP enhancement of lamellipodial dynamics, which support a role for water movement across the leading edge of migrating cells, as was proposed previously (Ref. 63 ). According to this hypothesis, actin depolymerisation and ion influx increase cytoplasmic osmolality at the front end of the migrating cell, driving water influx across the plasma membrane (Fig. 1c) . Water influx would thus expand the adjacent plasma membrane by increased local hydrostatic pressure, followed by actin repolymerisation to stabilise the cell membrane protrusion. There is evidence that regional hydrostatic pressure changes within cells do not equilibrate throughout the cytoplasm on scales of 10 mm and 10 s (Ref. 64) , and could thus contribute to the formation of localised cell membrane protrusions. Further studies, including direct measurements of water flow across the leading edge of migrating cells, are needed to validate these ideas. 
Neural signal transduction
Possible mechanisms of impaired neuroexcitation in AQP4 deficiency
The mechanisms for altered neuroexcitation in AQP4 deficiency are unclear at present (Fig. 1d) Perhaps reduced water permeability in AQP4 deficiency may be responsible for defective neuroexcitation function by a mechanism involving impaired cell volume responses. Alternative possible mechanisms include AQP4 interaction with key ion channels, perhaps through PDZ-domain interactions, and maladaptive regulation in AQP4 deficiency of other transporters involved in neuroexcitation.
Glycerol transport by the aquaglyceroporins
For many years the physiological significance of glycerol transport by the aquaglyceroporins was unclear. Phenotype studies of mice lacking aquaglyceroporins have produced a number of remarkable findings for the involvement of AQP3 in epidermal biology and cell proliferation, and of AQP7 in adipocyte metabolism. A recent report on AQP9-null mice showed a subtle phenotype suggestive of impaired hepatic glycerol uptake (Ref. 74) , although the mechanism remains to be established as does its proposed significance to diabetes.
AQP3 and skin function
The stratum corneum (SC) is the most superficial layer of skin, consisting of a lamellar lipid layer and terminally differentiated keratinocytes that originate from actively proliferating keratinocytes in lower epidermis. SC hydration is an important determinant of skin appearance and physical properties, and depends on several factors including the external humidity, and SC structure, lipid/protein composition, barrier properties, and concentration of waterretaining osmolytes. AQP3 is expressed strongly in the basal layer of keratinocytes (Fig. 5a ). SC hydration is reduced in AQP3-null mice as measured by high-frequency skin conductance (Ref. 75) (Fig. 5b) , which is a linear index of SC water content. Exposure of mice to high humidity or occlusion increased SC hydration in wild-type, but not AQP3-null mice, indicating that water transport through AQP3 is not a rate-limiting factor in transepidermal water loss. If reduced SC hydration is related to a balance between evaporative water loss from the SC and water replacement through AQP3-containing basal keratinocytes, then preventing water loss by high humidity or occlusion should have corrected the defect in SC hydration in AQP3-null mice, which it did not. Skin phenotype analysis also indicated delayed barrier recovery after SC removal by tape-stripping in AQP3-null mice, as well as decreased skin elasticity and delayed wound healing (Ref. 75) .
A systematic analysis of SC and epidermal ultrastructure and composition revealed reduced glycerol content in SC and epidermis (Fig. 5c) , with normal glycerol in dermis and serum, suggesting reduced glycerol transport from blood into the epidermis in AQP3 deficiency through the basal keratinocytes (Fig. 1e) . No significant differences in wild-type versus AQP3-null mice were found in SC structure, cell turnover, lipid profile, protein content, and the concentrations of amino acids, ions and other small solutes (Ref. 76 ). These observations suggest that reduced epidermal and SC glycerol content is responsible for the abnormal skin phenotype in AQP3-null mice. Because glycerol is a water-retaining osmolyte, or 'natural moisturising factor', reduced SC expert reviews http://www.expertreviews.org/ in molecular medicine glycerol reduces SC hydration and skin elasticity; furthermore, because of its biosynthetic role in the epidermis (see next section), reduced epidermal glycerol is predicted to delay barrier recovery function and wound healing. 
AQP3 and cell proliferation
Recent data support the unexpected involvement of AQP3 in cell proliferation in certain cell types. Remarkably, mice lacking AQP3 failed to produce cutaneous papillomas in an inducer-promoter model of skin cancer, whereas wild-type mice produced multiple tumours ( Fig. 5d) Experiments to establish the cellular mechanisms responsible for the impaired tumourigenesis phenotype showed impaired promoter-induced cell proliferation in AQP3-null or -knockdown keratinocyte cell cultures. AQP3-deficient keratinocytes had reduced content of glycerol, its metabolite glycerol-3-phosphate, and ATP, without impairment of mitochondrial function. Glycerol supplementation or AQP3 adenoviral infection (but not AQP1 adenoviral infection) corrected the defects in keratinocyte proliferation and increased ATP. Further studies revealed correlations between cell proliferation, and ATP and glycerol content. It was proposed that AQP3-facilitated glycerol transport is an important determinant of epidermal cell proliferation and tumourigenesis by a mechanism in which glycerol is a key regulator of cellular ATP energy (Fig. 1f) . The mechanism also shows glycerol biosynthetic incorporation into lipids, and positive feedback in which cell proliferation increases AQP3 expression. These findings have potential implications in the prevention and therapy of skin and other cancers, and raise concerns in the use of cosmetics containing ingredients that increase epidermal AQP3 expression whose goal is to improve skin moisture and appearance (Ref. 80 ).
AQP7 and fat metabolism
AQP7 is expressed in the plasma membrane of adipocytes. Although wild-type and AQP7-null mice grow at similar rates as assessed by mouse weight, over time AQP7-null mice develop significantly greater fat mass compared with wild-type mice (Ref. 81) . Adipocytes from adult AQP3-null mice are several-fold larger than those from wild-type mice, suggesting that the greater fat mass in the AQP7-null mice is a consequence of adipocyte hypertrophy. Concentrations of glycerol and triglycerides in serum were unaffected by AQP7 deletion, but adipocyte glycerol and triglyceride concentrations were significantly elevated in AQP7-null mice, suggesting a mechanism for the progressive adipocyte hypertrophy in AQP7 deficiency.
Plasma membrane glycerol permeability was reduced significantly in adipocytes of AQP7-null mice, as was glycerol release. However, lipolysis, as measured by free fatty acid release from isolated adipocytes, was similar in wild-type and AQP7-deficient mice, as was lipogenesis, as assayed from the incorporation of [
14 C]glucose into triglycerides. From these results, we proposed a simple mechanism for progressive triglyceride accumulation in AQP7-deficient adipocytes (Fig. 1g) , in which reduced plasma membrane glycerol permeability in AQP7 deficiency produces an increased glycerol concentration in adipocyte cytoplasm, resulting in increased glycerol-3-phosphate and triglyceride biosynthesis. Similar conclusions about fat metabolism in AQP7 deficiency were reported independently (Ref. 82) , although with some relatively minor differences in phenotype findings compared with our results. It was speculated that AQP7 plays an important role in the pathogenesis of human obesity (reviewed in Ref. 83) , although whether this is the case remains to be determined.
Clinical implications/applications
Notwithstanding differences in mouse versus human physiology, the involvement of AQPs in major physiological processes in mouse models likely has a number of clinical implications. The requirement of AQPs for the formation of a concentrated urine suggests that AQP inhibitors, or 'AQP-aquaretics', would act as unique diuretics with potential utility in diuretic-refractory oedematous states such as severe congestive heart failure. Inhibitors of various AQPs are also predicted to have potential efficacy in reducing water entry into the brain in cytotoxic oedema, in improving the outcome following spinal cord injury, in reducing aqueous fluid production in glaucoma, in inhibiting glial scar formation, in reducing angiogenesis and tumour spread, in reducing cell proliferation in certain cancers, and in increasing seizure threshold in epilepsy.
Drugs that increase AQP function, acting for example by increasing AQP expression, are predicted to have potential efficacy in reducing fat mass in obesity, in accelerating brain water clearance in vasogenic oedema, and in promoting wound healing and tissue regeneration following injury. Validation of these predictions will require the development of appropriate AQP-specific modulators. Another AQP-related clinical application is in disease diagnosis, as demonstrated for serum AQP4 autoantibodies in diagnosing the optic -spinal form of multiple sclerosis (Ref. 84) , and for urinary AQP2 protein in distinguishing among various aetiologies of nephrogenic diabetes insipidus (Ref. 85 ). Other AQP-related disease markers are likely to be identified. The possibility of AQP polymorphisms contributing to human disease is largely unexplored. It would be worthwhile, for example, to investigate polymorphisms in AQP4 in brain diseases such as hydrocephalus, in AQP3 in skin diseases, and in various AQPs in cancer. Last, the modulation of AQP expression in disease states may be clinically important. In some cases altered AQP expression appears to be a maladaptive response, as in the case of reduced renal AQP2 expression in various forms of polyuria, which further impairs urinary concentrating ability (Ref. 86) , and AQP4 upregulation in various aetiologies of brain swelling, which may exacerbate brain water accumulation. There is an expanding literature on altered AQP expression in human diseases, with evidence for altered AQP3 expression in skin diseases (Ref. 87 ), AQP4 expression in epilepsy (Ref. 88) , and AQP7 expression in obesity and metabolic diseases (Ref. 89) . In most cases, however, it will likely be difficult to establish the cellular mechanisms and clinical significance of such observations.
Research in progress and outstanding research questions
There remain many unanswered questions about the roles of AQPs in mammalian physiology, as well as exciting opportunities for clinical applications. Although water transport has been studied for many decades and AQP proteins were identified in the early 1990s, many of the new AQP cellular functions were recognised only in the past few years, so it is likely that additional new AQP functions will be discovered. Much work remains in the precise elucidation of cellular mechanisms responsible for AQP involvement in cell migration, neural signal transduction and in vasogenic brain oedema, and in the precise role of the aquaglyceroporins in cellular metabolism and proliferation. Finally, as mentioned in the previous section, identification of chemical AQPselective modulators is a high priority in ongoing research, as small-molecule AQP inhibitors and upregulators have the potential to serve as new tools to study AQP function and as potential therapies for major human diseases.
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